ACAD Acadia Pharmaceuticals Inc

Price (delayed)

$17.56

Market cap

$2.82B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.65

Enterprise value

$2.61B

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who ...

Highlights
ACAD's gross profit is up by 19% year-on-year
ACAD's revenue is up by 18% YoY
The quick ratio has declined by 22% year-on-year but it is up by 10% since the previous quarter
The net income has declined by 16% year-on-year
The company's equity fell by 15% YoY and by 2.9% QoQ

Key stats

What are the main financial stats of ACAD
Market
Shares outstanding
160.64M
Market cap
$2.82B
Enterprise value
$2.61B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.98
Price to sales (P/S)
6.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.63
Earnings
Revenue
$463.36M
EBIT
-$261.03M
EBITDA
-$257.66M
Free cash flow
-$140.6M
Per share
EPS
-$1.65
Free cash flow per share
-$0.88
Book value per share
$3.53
Revenue per share
$2.89
TBVPS
$4.51
Balance sheet
Total assets
$724.43M
Total liabilities
$159.59M
Debt
$59.13M
Equity
$564.84M
Working capital
$550.4M
Liquidity
Debt to equity
0.1
Current ratio
6.77
Quick ratio
6.45
Net debt/EBITDA
0.83
Margins
EBITDA margin
-55.6%
Gross margin
98%
Net margin
-56.5%
Operating margin
-56.9%
Efficiency
Return on assets
-34.2%
Return on equity
-43.1%
Return on invested capital
-70.2%
Return on capital employed
-41.5%
Return on sales
-56.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACAD stock price

How has the Acadia Pharmaceuticals stock price performed over time
Intraday
0%
1 week
-2.34%
1 month
0.86%
1 year
-62.12%
YTD
-67.15%
QTD
5.72%

Financial performance

How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$463.36M
Gross profit
$454.14M
Operating income
-$263.54M
Net income
-$261.74M
Gross margin
98%
Net margin
-56.5%
ACAD's gross profit is up by 19% year-on-year
ACAD's revenue is up by 18% YoY
The net income has declined by 16% year-on-year
The operating income has contracted by 12% YoY

Growth

What is Acadia Pharmaceuticals's growth rate over time

Valuation

What is Acadia Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.98
P/S
6.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.63
The EPS has decreased by 12% YoY
ACAD's price to book (P/B) is 47% lower than its last 4 quarters average of 9.4 and 46% lower than its 5-year quarterly average of 9.2
The company's equity fell by 15% YoY and by 2.9% QoQ
ACAD's P/S is 82% below its 5-year quarterly average of 34.7 and 53% below its last 4 quarters average of 13.0
ACAD's revenue is up by 18% YoY

Efficiency

How efficient is Acadia Pharmaceuticals business performance
ACAD's return on invested capital is down by 30% year-on-year but it is up by 3% since the previous quarter
The ROE has contracted by 29% YoY and by 4.6% from the previous quarter
Acadia Pharmaceuticals's return on assets has decreased by 16% YoY

Dividends

What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACAD.

Financial health

How did Acadia Pharmaceuticals financials performed over time
The total liabilities has soared by 65% YoY but it has decreased by 8% QoQ
The quick ratio has declined by 22% year-on-year but it is up by 10% since the previous quarter
The debt is 90% lower than the equity
The company's equity fell by 15% YoY and by 2.9% QoQ
The debt has decreased by 2.4% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.